Frequency
Fukuyama congenital muscular dystrophy is more common among people of Japanese ancestry. It is estimated to affect 1 in 25,000 to 50,000 infants born in Japan.
Causes
Fukuyama congenital muscular dystrophy is caused by variants (also called mutations) in the FKTN gene. This gene provides instructions for making an enzyme called fukutin. Fukutin modifies another protein called alpha-dystroglycan. This modification is necessary for alpha-dystroglycan to function. Alpha-dystroglycan anchors cells to the extracellular matrix, which is the network of molecules that forms in the spaces between cells and provides structural support. In skeletal muscles, alpha-dystroglycan helps stabilize and protect muscle fibers. In the brain, alpha-dystroglycan helps direct the movement (migration) of nerve cells (neurons
) during early development.
The most common variant in the FKTN gene reduces the amount of fukutin produced within cells. This impairs the cell's ability to produce functional alpha-dystroglycan. Without enough functional alpha-dystroglycan to stabilize muscle cells, muscle fibers become damaged as they repeatedly contract and relax with use. The damaged fibers weaken and die over time, leading to progressive weakness and atrophy of the skeletal muscles.
The lack of functional alpha-dystroglycan also impairs the migration of neurons during the early development of the brain. This leads to the cobblestone lissencephaly seen in children with Fukuyama congenital muscular dystrophy.
Because Fukuyama congenital muscular dystrophy involves problems with alpha-dystroglycan, the condition belongs to a group of disorders called dystroglycanopathies.
Inheritance
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.
Other Names for This Condition
- Congenital muscular dystrophy, Fukuyama type
- FCMD
- FKTN-related congenital muscular dystrophy
- MDDGA4
- Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4
Additional Information & Resources
Genetic and Rare Diseases Information Center
Patient Support and Advocacy Resources
Clinical Trials
Catalog of Genes and Diseases from OMIM
Scientific Articles on PubMed
References
- Agarwal A, Sabat S, Kanekar S. Fukuyama Congenital Muscular Dystrophy. Cureus. 2022 Feb 4;14(2):e21902. doi: 10.7759/cureus.21902. eCollection 2022 Feb. Citation on PubMed
- Martin PT. Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage. Nat Clin Pract Neurol. 2006 Apr;2(4):222-30. doi: 10.1038/ncpneuro0155. Citation on PubMed or Free article on PubMed Central
- Saito K. Fukuyama Congenital Muscular Dystrophy. 2006 Jan 26 [updated 2019 Jul 3]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1206/ Citation on PubMed
- Toda T, Kobayashi K, Takeda S, Sasaki J, Kurahashi H, Kano H, Tachikawa M, Wang F, Nagai Y, Taniguchi K, Taniguchi M, Sunada Y, Terashima T, Endo T, Matsumura K. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. Congenit Anom (Kyoto). 2003 Jun;43(2):97-104. doi: 10.1111/j.1741-4520.2003.tb01033.x. Citation on PubMed
- Yoshioka M, Higuchi Y, Fujii T, Aiba H, Toda T. Seizure-genotype relationship in Fukuyama-type congenital muscular dystrophy. Brain Dev. 2008 Jan;30(1):59-67. doi: 10.1016/j.braindev.2007.05.012. Epub 2007 Jun 26. Citation on PubMed
- Yoshioka M, Kuroki S. Clinical spectrum and genetic studies of Fukuyama congenital muscular dystrophy. Am J Med Genet. 1994 Nov 15;53(3):245-50. doi: 10.1002/ajmg.1320530309. Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.